CF Epidemiology: Australia
Transcript of CF Epidemiology: Australia
![Page 1: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/1.jpg)
Cystic Fibrosis
![Page 2: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/2.jpg)
1938
CYSTIC FIBROSIS OF THE PANCREAS
AND ITS RELATION TO CELIAC
DISEASE.
D ANDERSEN.
American Journal Diseases Children.
![Page 3: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/3.jpg)
Cystic Fibrosis : The beginning
0
5
10
15
20
25
Nos of cases
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Age at death
May 1938: 49 cases
![Page 4: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/4.jpg)
Cystic Fibrosis
Commonest lethal inherited condition in WW
Life limiting and incurable.
600 patients in Victoria with CF.
One in every 2,500 live births
About 15-25 new born pts per year in Vict
![Page 5: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/5.jpg)
Cystic Fibrosis
Median age survival late 30’s
95% survive till 20 years
80% till 30 years
![Page 6: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/6.jpg)
Cystic Fibrosis
New Born screening: Hits
All states of Australia
Day 3
2 part test: IRT and CF gene
Positive results by 4-6 weeks
![Page 7: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/7.jpg)
Cystic Fibrosis
New Born screening
2 part test: IRT top 1%
CF genotype
![Page 8: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/8.jpg)
Cystic Fibrosis
State
New South Wales + ACT
Victoria + Tasmania
Queensland
South Australia + Northern Territory
Western Australia
Mutations screened
508
p.F508, del,c.489+1G>T, c.1585-1G>A,
c.3718-2477C>T, p.1507del, p.W1282X,
p.R553X, p.R560T, p.N1303K, p.G542X,
p.G551D, p.V520F
508, I507, G551D, G542X, 621+1GT
R553X N1303K, R117H, p.V520F
508, I507, G551D, G542X, R553X
508, G551D, G542X, 621+1GT
![Page 9: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/9.jpg)
Cystic Fibrosis
CF gene:
Over 1900 different mutations
508 commonest - present in 90% pts in Australia
Current Vic program screens for 12 commonest
Mutations screened for differ between states
![Page 10: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/10.jpg)
Cystic Fibrosis Transmembrane Regulator
![Page 11: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/11.jpg)
![Page 12: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/12.jpg)
CYSTIC FIBROSIS
GENOTYPES
Class 1: Premature termination of mRNA translation
due to base substitution causing stop codons
or mutations that shift the reading frame
Producing defective proteins
![Page 13: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/13.jpg)
![Page 14: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/14.jpg)
![Page 15: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/15.jpg)
![Page 16: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/16.jpg)
CYSTIC FIBROSIS
GENOTYPES
Class 2: Defects in protein processing
CFTR is degraded in ER and does not reach
apical membrane
508 and N1303K
![Page 17: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/17.jpg)
![Page 18: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/18.jpg)
CYSTIC FIBROSIS
GENOTYPES
Class 3: Regulatory mutations
CFTR reaches apical membrane but fails
respond to activation signals
G551D
![Page 19: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/19.jpg)
![Page 20: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/20.jpg)
CYSTIC FIBROSIS
GENOTYPES
Class 4: Defective protein conduction
Reaches apical membrane but has altered
channel properties
R117H and R347P
![Page 21: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/21.jpg)
![Page 22: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/22.jpg)
CYSTIC FIBROSIS
GENOTYPES
Class 5: Reduced levels of RNA for CFTR
![Page 23: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/23.jpg)
![Page 24: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/24.jpg)
Cystic Fibrosis
New Born screening: Misses
Chronic Cough
![Page 25: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/25.jpg)
![Page 26: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/26.jpg)
![Page 27: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/27.jpg)
![Page 28: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/28.jpg)
![Page 29: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/29.jpg)
Cystic Fibrosis
New Born screening: Misses
Chronic Cough
Failure to thrive
![Page 30: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/30.jpg)
Cystic Fibrosis
New Born screening: Misses
Chronic Cough
Failure to thrive
Chronic Diarrhoea
![Page 31: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/31.jpg)
![Page 32: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/32.jpg)
![Page 33: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/33.jpg)
Underlying defect in CF
![Page 34: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/34.jpg)
Mechanisms of lung damage in CF
Infection Inflammation
Lung damage
Abnormal lung function
Death
Viscous
secretions
CFTR
dysfunction
![Page 35: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/35.jpg)
CF : Early lung disease
Aim to minimise/ delay onset disease
thru new born screening
![Page 36: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/36.jpg)
Early intervention in CF patients
prevents severe malnutrition
• Wisconsin CF Neonatal Screening Study
• Randomised controlled trial with 650,000 newborns.
Split into two groups:
– an early-diagnosis screened cohort
– a standard diagnosis control group
• Newborns screened for CF by
– immunoreactive trypsinogen (IRT) test (1985-91)
– IRT test + DNA-based detection of F508 (1991-94)
![Page 37: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/37.jpg)
Effect of screening on weight
-1.8
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Screened
Unscreened
We
igh
t S
DS
p<0.05
![Page 38: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/38.jpg)
CF update: Early lung disease
Aim to minimise thru NBS
Regular assessments: BAL
CT Scans
PFT’s
![Page 39: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/39.jpg)
CF update: Early lung disease
Regular assessments: BAL
30% infants will have Pseudomonas by age 3
Linnane B
![Page 40: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/40.jpg)
CF update: Early lung disease
Regular assessments: BAL
30% infants will have Pseudomonas by age 3 despite
aggressive cross infection policies
![Page 41: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/41.jpg)
CF update: Early lung disease
Regular assessments: BAL
30% infants will have Pseudomonas by age 3 despite
aggressive cross infection policies
Aggressive eradication programs – 85% successful
![Page 42: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/42.jpg)
CF update: Early lung disease
Regular assessments: BAL
30% infants will have Pseudomonas by age 3 despite
aggressive cross infection policies
Aggressive eradication programs – 85% successful
Pseudomonas EVER is a bad prognostic factor
![Page 43: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/43.jpg)
CF update: Early lung disease
Regular assessments: CT scans
90% infants will show signs of bronchiectasis
on CT at age 5 years
Wainwright C
![Page 44: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/44.jpg)
CF update: Early lung disease
Regular assessments: PFT’s
Changes occur very early and are progressive
![Page 45: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/45.jpg)
Linnane B
![Page 46: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/46.jpg)
![Page 47: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/47.jpg)
CF update Antibiotic therapy in CF
Targeted
Non Pseudomonal: Staph/ H Inf
![Page 48: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/48.jpg)
Incidence airway pathogens by age
0
20
40
60
80
100
0-1 2-5 6-10 11-15 16-20 21-25 26-30 31-35 >35
S. aureus
H. influenzae
Age group (years)
To
tal cu
ltu
res (
%)
![Page 49: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/49.jpg)
![Page 50: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/50.jpg)
CYSTIC FIBROSIS
B. CEPACIA
Genomovars (1-9)
Aggressive lung disease (cenocepacia type 3)
Non 3 mild disease
Bactrim/Colistin/minocycline
Some clearance
![Page 51: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/51.jpg)
![Page 52: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/52.jpg)
CYSTIC FIBROSIS
ASPERGILLUS
ABPA
Airway colonisation
Aspergilloma
Infection in pre existing cyst
![Page 53: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/53.jpg)
ABPA
(ABPA) Allergic bronchopulmonary aspergillosis is a condition
characterised by an exaggerated TH2 CD4+ immune response to the fungus
Aspergillus (most commonly Aspergillus fumigatus).
Diagnosis of ABPA in CF is difficult, and may often be delayed, because many
of the diagnostic criteria overlap with common manifestations of CF
![Page 54: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/54.jpg)
ABPA Classic case(all five required)
1. Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise-induced asthma, decline in pulmonary function, increased sputum) not attributable to another etiology.
2. Serum total IgE concentration of >1000 IU/mL (2400 ng/mL), unless patient is receiving systemic corticosteroids
3. Immediate cutaneous reactivity to Aspergillus (prick skin test wheal of >3 mm with surrounding erythema, or elevated IgE antibody to A. fumigatus
4. Precipitating antibodies to A. fumigatus or serum IgG antibody to A. fumigatus
5. New or recent abnormalities on chest radiography (infiltrates or mucus plugging) or chest CT (bronchiectasis) that do not clear with Ab’s and physio.
![Page 55: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/55.jpg)
ABPA Minimal diagnostic criteria (all four required)
1. Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise-induced asthma, change in pulmonary function, or increased sputum production) not attributable to another etiology.
2. Total serum IgE concentration of >500 IU/mL (1200 ng/mL) off steroids.
3. Immediate cutaneous reactivity to Aspergillus (prick skin test wheal of >3 mm or elevated specific IgE antibody to A. fumigatus.
4. One of the following: (a) precipitins to A. fumigatus or in vitro demonstration of IgG antibody to A. fumigatus; or (b) new or recent abnormalities on chest radiography
![Page 56: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/56.jpg)
![Page 57: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/57.jpg)
Incidence airway pathogens by age
0
20
40
60
80
100
0-1 2-5 6-10 11-15 16-20 21-25 26-30 31-35 >35
P. aeruginosa
S. aureus
H. influenzae
Age group (years)
To
tal cu
ltu
res (
%)
![Page 58: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/58.jpg)
CF update Antibiotic therapy in CF
Targeted
Main challenge is Pseudom
Still limited to Tobra/ Cipro (Colistin)
Cayston – BD ineffective
Initial eradication phase
Regular cycling suppressive courses
![Page 59: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/59.jpg)
Pseudomonas therapy
Reculture:
Sputum or BAL
POSITIVE NEGATIVE
2 weeks of IV anti-
pseudomonal
antibiotics and then
repeat
No further treatment or
back to prophylactic
antibiotics
If following second attempt of eradication sputum or
BAL is still positive is likely chronic Pa infection
+ve sample
culture for
P.
aeruginosa
Nebulised tobramycin
Cipro Cipro
3 months
? IV’s
![Page 60: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/60.jpg)
P. aeruginosa:
Early colonisation to chronic infection
Progression from intermittent colonisation to chronic
infection coincides with activation of gene coding
for alginate production
![Page 61: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/61.jpg)
Pseudomonas treatment
Compared the clinical and microbiological effectiveness
as well as the safety of 4 antibiotic treatment strategies
for newly identified P aeruginosa infection isolated
from respiratory cultures in children with CF.
Treggiari Arch Pediatr Adolesc Med. 2011;165(9):847-856
![Page 62: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/62.jpg)
Pseudomonas treatment
10 end point: Time to pulmonary exacerbation requiring IV’s
and
% of P aeruginosa +ve cultures.
Treggiari Arch Pediatr Adolesc Med. 2011;165(9):847-856
![Page 63: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/63.jpg)
Pseudomonas treatment
304 pts there were no statistically significant differences in
exacerbation rates or in prevalence of Pseud between cycled and culture-based groups.
Treggiari Arch Pediatr Adolesc Med. 2011;165(9):847-856
![Page 64: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/64.jpg)
Pseudomonas treatmentAdding ciprofloxacin produced no benefits.
Treggiari Arch Pediatr Adolesc Med. 2011;165(9):847-856
![Page 65: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/65.jpg)
P. aeruginosa: From early colonisation
to chronic infection
Progression from intermittent colonisation to chronic
infection coincides with activation of gene coding
for alginate production
Transition coincides with increase in specific serum
anti-P. aeruginosa antibodies (exotoxin A)
![Page 66: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/66.jpg)
P. aeruginosa: From early colonisation
to chronic infection
Progression from intermittent colonisation to chronic infection coincides with activation of gene coding for alginate production
Transition coincides with increase in specific serum anti-P. aeruginosa antibodies (exotoxin A)
Activation of alginate gene may be caused by hydrogen peroxide released from activated PMNs
![Page 67: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/67.jpg)
Cumulative age of patients with
chronic P. aeruginosa infection
0
20
40
60
80
100
0 5 10 15 20 25 30 35 40 45 50
1975 (n=55)
1980 (n=107)
1985 (n=123)
1990 (n=130)
1995 (n=131)
Age (years)
%
![Page 68: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/68.jpg)
40
50
60
70
80
90
100
7 8 9 10 11 12 13 14 15 16 17Age in years
Percen
t p
red
ictd
FVC FEV
P. aeruginosa negative - Mean %
predicted of spirometry parameters
40
50
60
70
80
90
100
7 8 9 10 11 12 13 14 15 16 17
Age in years
Percen
t p
red
ictd
FVC FEV
P. aeruginosa positive - Mean %
predicted of spirometry parameters
Small airways and lung function
![Page 69: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/69.jpg)
Stenotrophomonas maltophilia in CF
Pts with chronic S. maltophilia infection had significantly
increased risk of pulmonary exacerbation requiring
hospitalization and antibiotics compared pts who had never
had S. maltophilia.
![Page 70: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/70.jpg)
P. aeruginosa: From early colonisation
to chronic infection
Macrolide antibiotics suppress alginate production in vitro
Azithromycin treatment leads to increase in FVC and FEV1 in patients with chronic P. aeruginosa infection
Not effective in non Pseudomonas cases (Saiman)
AZT therapy now widey used to stabilise established
lung disease M,W,F or daily 250 or 500 mg
Other macrolides not effective
![Page 71: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/71.jpg)
Macrolide therapy in CF
Clarithromycin Therapy for Patients With Cystic Fibrosis:
A Randomized Controlled Trial
P. Robinson, et al Pediatric Pulmonology 47:551–557 (2012).
![Page 72: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/72.jpg)
Prevalence of AES-1
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
A1(n=20)
A2(n=117)
A3(n=52)
A4(n=20)
A5(n=14)
B1(n=68)
B2(n=85)
B3(n=47)
C1(n=57)
C2(n=174)
C3(n=20)
C4(n=38)
C5(n=16)
C6(n=6)
D1(n=72)
D2(n=24)
E1(n=93)
F1(n=28)
Overall(n=951)
Pe
rce
nt
pre
va
len
ce
State/Centre
AES-1Range:0.0% – 44.7% AES-1 detected in 17/18 centres
![Page 73: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/73.jpg)
Prevalence of AES-2
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
A1(n=20)
A2(n=117)
A3(n=52)
A4(n=20)
A5(n=14)
B1(n=68)
B2(n=85)
B3(n=47)
C1(n=57)
C2(n=174)
C3(n=20)
C4(n=38)
C5(n=16)
C6(n=6)
D1(n=72)
D2(n=24)
E1(n=93)
F1(n=28)
Overall(n=951)
Pe
rce
nt
pre
va
len
ce
State/Centre
Range:0.0% – 66.7%
AES-2AES-2 detected in 16/18 centres
![Page 74: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/74.jpg)
CF updateAntibiotic therapy in CF:
Prophylactic
Anti Staph treatment till 2 years age
50% treatment dose of Augmentin or Fluclox
![Page 75: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/75.jpg)
CF updateAntibiotic therapy in CF:
Prophylactic
Anti Staph treatment till 2 years age
50% treatment dose of Augmentin or Fluclox
Anti Pseudomonal therapy (neb tobra)
in select cases
![Page 76: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/76.jpg)
CF update
New therapies
Mucolytic therapies – new ones
![Page 77: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/77.jpg)
CF update
Mucolytic therapies
New ones
Inhaled mannitol
Denufosol
![Page 78: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/78.jpg)
CF update
Mucolytic therapies
New ones
Inhaled mannitol
Pulmozyme over 5 years age
Hypertonic saline 3-6%
![Page 79: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/79.jpg)
Elkins M et al. N Engl J Med 2006;354:229-240
Elkins M
![Page 80: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/80.jpg)
Inhaled mannitol
![Page 81: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/81.jpg)
Mannitol - A naturally occurring sugar alcohol.
• A potent osmotic agent
• Mannitol dry powder
– Respirable particles - 3µm
– No carrier
– Small portable inhaler
– No cleaning or preparation time
– 400mg = 10 x 40mg caps (bd)
– 3 – 5 minutes dosing time
![Page 82: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/82.jpg)
Healthy Mucociliary System
Thin film of mucus
Airway Surface Liquid
Submucosal glands
Cilia
Goblet Cell
Ciliated Cell
Mucociliary system (normal)
Thin film of mucus
Airway Surface Liquid
Submucosal glands
Cilia
Goblet Cell
Ciliated Cell
![Page 83: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/83.jpg)
Mucus surface
properties
changed
Airway Surface
Liquid
reconstituted
Cilia
function
improved
H2OH2O H2O H2O
H2O
Goblet Cell
Ciliated Cell
1
3
2
4 Cough60 mm/s
1. Mannitol alters the rheological properties of mucus
2. Mannitol increases the volume of airway surface liquid (ASL)
3. Mannitol has shown to have an indirect effect on cilia beat frequency in
in-vitro studies
4. Mannitol promotes productive cough and assists in clearing mucus- Difference between productive cough and impact cough
Mode of Action of Mannitol
![Page 84: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/84.jpg)
CF-301 Mean % change in FEV1
Bilton D, Robinson P et al. European Respiratory Journal 2011:38:1071-1080
![Page 85: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/85.jpg)
CF update
Mucolytic therapies – new uses for old ones
Pulmozyme (dornase alpha)
![Page 86: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/86.jpg)
CF update: Pulmozyme (dornase alpha)
Over 5 years age:
1 month trial showing 10% increase in FEV1 for continued therapy
![Page 87: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/87.jpg)
CF update: Pulmozyme (dornase alpha)
Over 5 years age:
1 month trial showing 10% increase in FEV1 for continued therapy
Removed 2013 now clinical grounds only
Under 5 years age:
Severe clinical course with > 3 admits
Signif bronchiectasis on CT scan
Severe CF bronchiolitis with persistent, resistant wheeze
Severe impairment on spirometry (FOT or MBW)
![Page 88: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/88.jpg)
CF update
New therapies: Mutation specific therapies
Vertex trials: G551D
![Page 89: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/89.jpg)
![Page 90: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/90.jpg)
Vx 102 and 103 trials
Evaluate the efficacy of VX-770 after 24 weeks of
treatment in subjects with CF who have the G551D-cystic
fibrosis trans membrane conductance regulator (CFTR)
mutation on at least 1 allele
102 CF pts above 12 years
103 CF 6-12 years
105 open label extension
![Page 91: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/91.jpg)
VX-770 Phase III Study Design 102
• Randomized, double-blind, placebo-controlled
• Recruitment: 161 subjects
• Key inclusion criteria
– G551D mutation on at least one CFTR allele
– Aged ≥ 12 years
– FEV1 40% to 90% predicted
Run-inScreening
Randomization(1:1)
Or
2-yr Follow-up
VX-770 150 mg q12h
Open-label
rollover study
Placebo Placebo
Day -35 -14 0 48Week 24
VX-770 150 mg q12h
VX-770 150 mg q12h
Treatment period Extension period
Primary analysis
![Page 92: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/92.jpg)
Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48
-5
0
5
10
15Placebo
VX-770
Ab
so
lute
ch
an
ge in
% p
red
icte
d F
EV
1
(mea
n,
95
% C
I)
Absolute Change in FEV1 % Predicted
Treatment effect through Week 24
+ 10.6 %P < 0.0001
Treatment effect through Week 48
+ 10.5 %P < 0.0001
![Page 93: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/93.jpg)
Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48
-60
-55
-50
-45
-40
-35
-30
-25
-20
-15
-10
-5
0
5
Placebo
VX-770
Ch
an
ge in
sw
eat
ch
lori
de c
on
cen
trati
on
mm
ol/
L (
me
an
, 9
5%
CI)
Change from Baseline in Sweat Chloride
Treatment effect through Week 24
– 47.9 mmol/LP < 0.0001
Treatment effect through Week 48
– 48.1 mmol/L P < 0.0001
![Page 94: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/94.jpg)
Change from Baseline in CFQ-R Resp Domain
Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48
-10
-8
-6
-4
-2
0
2
4
6
8
10
12
Placebo
VX-770Ch
an
ge
in
CF
Q-R
re
sp
irato
ry d
om
ain
po
ints
(m
ean
, 95
% C
I)
* MCID, minimal clinically important difference (Quittner et al 2009)
MCID = 4*
Treatment effect through Week 24
+ 8.1P < 0.0001
Treatment effect through Week 48
+ 8.6P < 0.0001
![Page 95: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/95.jpg)
Time to First Pulmonary Exacerbation
Week 24
Hazard Ratio
0.40 P = 0.0016
Week 48
Hazard Ratio
0.46 P = 0.0012
0.78
0.51
0.67
0.41
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Hazard Ratio: 0.45 ( 0.28, 0.73) P=0.0012
PLACEBO VX-770
Event-Free Rate At Week 48 0.41 0.67
PLACEBO VX-770
Event-Free Rate At Week 48
Placebo
VX-770
Pro
po
rtio
n o
f e
ve
nt-
fre
e s
ub
jec
ts
Study day
![Page 96: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/96.jpg)
Change from Baseline in Weight
Day 15 Week 8 Week 16 Week 24 Week 32 Week 40 Week 48
-1
0
1
2
3
4
5Placebo
VX-770
Ch
an
ge
in
we
igh
tkg
(m
ea
n,
95%
CI)
Treatment effect at Week 24
+ 2.8 kgP < 0.0001
Treatment effect at Week 48
+ 2.7 kgP = 0.0001
![Page 97: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/97.jpg)
![Page 98: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/98.jpg)
Lumicaftor
2 part medication
809 + Ivacaftor
3-4% increase in lung function
![Page 99: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/99.jpg)
CF updateComplications of getting older
Diabetes
20% CFRD by age of 20 years and up to 50% by mid thirties
Annual endocrine review after age 12 with consideration of
OGTT annually
![Page 100: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/100.jpg)
![Page 101: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/101.jpg)
![Page 102: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/102.jpg)
![Page 103: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/103.jpg)
![Page 104: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/104.jpg)
CF Related Diabetes mellitus (CFRD)
60% non-diabetic pts vs 25% diabetic pts lived to 30 yrs
US study, 21% CF patients with long-term diabetes had
microangiopathy, retinopathy, neuropathy, nephropathy
![Page 105: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/105.jpg)
![Page 106: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/106.jpg)
![Page 107: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/107.jpg)
Miscellaneous GI manifestations
Cancer:
Increased freq of small bowel, colon, biliary tract
No increase in stomach or rectum
Coeliac:
Previously thought to be increased but now found 10 times less common.
C. Difficile:
High carriage rate 20 to broad spectrum Ab’s
Crohn’s:
IBD 7 times more common, Crohns 17 times.
![Page 108: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/108.jpg)
Osteoporosis in CF
![Page 109: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/109.jpg)
Increasingly recognised in adults and children > 12
Children: 62 pts mean Z score -1.03 (spine) and 0.71
femoral neck. (Henderson).
Adults: mean Z score -1.21 (spine) and -1.25
(femoral neck)
Osteoporosis in CF
![Page 110: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/110.jpg)
Multifactorial
Malabsorption of Vit D and Calcium
Low body weight,
Decreased physical activity
Hypogonadism,
Osteolytic activity circulating cytokines,
Amenorrhea
Steroid usage
diabetes
Chronic infection,
Delayed puberty
Osteoporosis in CF
![Page 111: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/111.jpg)
CYSTIC FIBROSIS
DIAGNOSIS
Gold standard sweat test
Clinically think fat malabsorption
Prop develop PI nearer 12 months
5-10% PS – 95% destrn
![Page 112: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/112.jpg)
CYSTIC FIBROSIS
PANCREATIC INSUFFICENCY
Steathorrea most clinical obvious
Enzymes contain all 3 enzymes
Enteric coated
Acidic small bowel
Acid reducing agents
![Page 113: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/113.jpg)
Cystic Fibrosis
BOSTON TORONTO
n=499 (15.9yrs) n=534 (15.2yrs)
58% males 57% males
Fat restriction High fat diet
FEV1 = FEV1
![Page 114: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/114.jpg)
Cystic Fibrosis
BOSTON TORONTO
n=499 (15.9yrs) n=534 (15.2yrs)
58% males 57% males
Fat restriction High fat diet
FEV1 = FEV1
BUT
Median survival
21 years 30 years
![Page 115: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/115.jpg)
ASL
![Page 116: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/116.jpg)
ASL
In newborn wild-type pigs, the ASL rapidly kills bacteria
in vivo, when removed from the lung and in primary
epithelial cultures.
Lack of CFTR reduces bacterial killing.
AA Pezzulo et al. Nature 487, 109-113 (2012)
![Page 117: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/117.jpg)
AA Pezzulo et al. Nature 487, 109-113 (2012)
P. aeruginosa-coated
grids placed on HBE S. Aureus-coated
grids placed on HBE
![Page 118: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/118.jpg)
ASL
Found that the ASL pH was more acidic in CF pigs, and
reducing pH inhibited the antimicrobial activity of ASL.
![Page 119: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/119.jpg)
ASL
Without CFTR, airway epithelial HCO3 secretion is
defective, the ASL pH falls and inhibits antimicrobial
function, thereby impairing the killing of bacteria that
enter the newborn lung.
![Page 120: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/120.jpg)
Hypertonic saline
![Page 121: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/121.jpg)
Nebulised Hypertonic Saline (HTS)
CF lung inflammation mediated inflam chemokines, incl IL-8.
IL8 protected proteolytic degradation by binding to
glycosaminoglycans
Reeves Am J Respir Crit Care Med 2011; 183
![Page 122: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/122.jpg)
Nebulised Hypertonic Saline (HTS)
? anti-inflammatory effect of HTS in CF lung by focusing on IL-8
CF IL-8 levels significantly higher than the control group
Digesting glycosaminoglycans in CF BALF displaced IL-8 from
glycosaminoglycan matrices, rendering the chemokine susceptible
to proteolytic cleavage.
Reeves Am J Respir Crit Care Med 2011; 183
![Page 123: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/123.jpg)
Reeves Am J Respir Crit Care Med Vol 2011 183
![Page 124: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/124.jpg)
Nebulised Hypertonic Saline (HTS)
Nebulized HTS tx disrupts the interaction between IL-8
and glycosaminoglycans, rendering IL-8 susceptible to
proteolytic degradation with subsequent decrease in
neutrophil chemotaxis, facilitating resolution of
inflammation.
Reeves Am J Respir Crit Care Med Vol 2011 183
![Page 125: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/125.jpg)
Inhaled hypertonic saline in CF children < 6 yrs.
Multicenter, randomized, double-blind, placebo-controlled trial at 30 US CF centers in children 4 - 60 months.
Active treatment (158) received 7% HTS
Control group (163) received 0.9% isotonic saline,
nebulized bd for 48 weeks.
Mean pulmonary exacerbation rate was;
2.3 in HTS group and
2.3 in controls pts.
Rosenfeld ISIS Study Group. JAMA. 307(21):2269-77, 2012
![Page 126: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/126.jpg)
![Page 127: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/127.jpg)
Inhaled hypertonic saline in CF children < 6 yrs
No significant difference in secondary end points including height, weight, respiratory rate, oxygen saturation, cough, or respiratory symptom scores.
Rosenfeld ISIS Study Group. JAMA. 307(21):2269-77, 2012
![Page 128: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/128.jpg)
Bugs and drugs
![Page 129: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/129.jpg)
Pseudomonas and Females
Estradiol and estriol induced alginate production in P. aeruginosa strain 01 and in clinical isolates obtained from patients with and those without CF.
After prolonged exposure to estradiol, P. aeruginosa adopts mucoid morphology
Frameshift mutation was identified in mucA, a key regulator of alginate biosynthesis in P. aeruginosa
In vivo levels of estradiol correlated with infective exacerbations in
women with CF, with majority occurring during the follicular phase
Chotirmall N Eng J Med May 2012
![Page 130: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/130.jpg)
Chotirmall N Eng J Med May 2012
![Page 131: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/131.jpg)
Pseudomonas and Females
Predominantly nonmucoid P. aeruginosa was isolated from sputum
during exacerbations in the luteal phase (low estradiol).
Increased proportions of mucoid bacteria were isolated during
exacerbations occurring in the follicular phase (high estradiol),
Chotirmall N Eng J Med May 2012
![Page 132: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/132.jpg)
Azt autophagy
Autophagy: degradation of a cell's own components through the lysosomal system.
Autophagy appears crucial for an effective cellular response against mycobacteria including NTM.
Macrolide bafilomycin is known to disrupt autophagy in vitro.
Renna The Journal of Clinical Investigation 2011;121;(9)
![Page 133: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/133.jpg)
Azt autophagyStudies have identified synchronous increase in mycobacterial
infection of CF pts, predominantly with the multi-drug-resistant,
highly pathogenic nontuberculous mycobacteria Mycobacterium
abscessus.
Postulated azithromycin paradoxically impairs host immunity
against mycobacteria.
Renna The Journal of Clinical Investigation 2011;121;(9)
![Page 134: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/134.jpg)
Azt autophagyStudies have identified synchronous increase in mycobacterial
infection of CF pts, predominantly with the multi-drug-resistant,
highly pathogenic nontuberculous mycobacteria Mycobacterium
abscessus.
Postulated azithromycin paradoxically impairs host immunity
against mycobacteria.
Renna The Journal of Clinical Investigation 2011;121;(9)
![Page 135: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/135.jpg)
RENAL DISEASE IN CF
CFRD requiring insulin therapy substantially increased
the risk of chronic kidney disease.
Pulmonary exacerbations did not significantly increase
the risk of chronic kidney disease.
![Page 136: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/136.jpg)
Pseudomonas aeruginosa Type-3 Secretion
System Dampens Host Defense by Exploiting
the NLRC4-coupled Inflammasome
![Page 137: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/137.jpg)
Structures of needle proteins and their complexes.
Blocker A J et al. PNAS 2008;105:6507-6513
©2008 by National Academy of Sciences
![Page 138: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/138.jpg)
By “capping’ the TSSS there would be less intracellular
injection of bacterial toxins and less cell injury.
![Page 139: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/139.jpg)
Cellular inflammation
During an infection, one of the first forms of defense employed by the
innate immune response is a group of pattern recognition receptors
(PRRs) encoded in the germline to recognize molecular patterns expressed
by invading pathogens.
May either be on the membrane surface e.g. Toll-like receptors (TLRs)
and C-type Lectin Receptors (CLRs) or inside the cytoplasm e.g. Nod-like
receptors (NLRs).
Nod = nucleotide-binding oligomerization domain receptors
Oligomerization (chemistry) The formation of an oligomer from a
monomer
![Page 140: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/140.jpg)
INFLAMMASOME
In 2002, it was reported that a subset of NLRs named NLRP1 were able to
assemble and oligomerize into a common structure which collectively activated
the caspase-1 cascade, thereby leading to the production of pro-inflammatory
cytokines especially IL-1B and IL-18. This NLRP1 multi-molecular complex
was dubbed the ‘inflammasome’.
Since then, several other inflammasomes were discovered, two of which are also
NLR subsets—NLRP3 and NLRC4
![Page 141: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/141.jpg)
![Page 142: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/142.jpg)
![Page 143: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/143.jpg)
![Page 144: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/144.jpg)
Pseudomonas aeruginosa triggers, through a
functional type-3 secretion system (T3SS), the
activation of an intracellular cytosolic sensor
of innate immunity, NLRC4.
![Page 145: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/145.jpg)
Pseudomonas aeruginosa triggers through a functional type-3 secretion system (T3SS), the activation of an intracellular cytosolic sensor of innate immunity, NLRC4.
However,
NLRC4-inflammasome–dependent response contributes to increased clearance of intracellular pathogens, while Pseudomonas is an extracellular pathogen.
![Page 146: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/146.jpg)
Congenital abnormalities
Laryngomalacia
Clinical diagnosis
Bronchoscopy for Diff Dx
Resolution 2-3 years
Residual insp flow limitation
![Page 147: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/147.jpg)
Congenital abnormalities
Laryngomalacia
Clinical diagnosis
Bronchoscopy for Diff Dx
Resolution 2-3 years
Residual insp flow limitation
Diff Dx: tracheomalacia, sub-glottic haemangioma,
sug glottic cyst, paralysed vocal cord
![Page 148: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/148.jpg)
![Page 149: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/149.jpg)
Congenital abnormalities
Tracheomalacia:
Isolated, 20 TOF,
Cartilage rings, stenosis
aberrant airway anatomy
External compression
Bronchogram vs bronchoscopy
Stenting
![Page 150: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/150.jpg)
![Page 151: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/151.jpg)
Congenital abnormalities
Tracheomalacia:
20 TOF, vascular ring
Surgical repair does not improve
Pulm fnctn in short term
Dying spells
![Page 152: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/152.jpg)
Congenital abnormalities
Pulmonary hypoplasia:
Isolated
Compression – diaph hernia
Reduced lung function
Check vascular anatomy
![Page 153: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/153.jpg)
Bronchopulmonary Sequestration
A non-functioning mass of lung tissue that lacks normal communication with the tracheobronchial tree and receives its arterial blood supply from the systemic circulation usually from the thoracic or abdominal aorta.
2 types based on the nature of their pleural covering.
Extralobar sequestration is a mass of pulmonary parenchyma with a distinct pleura covering separating it from the adjacent normal lung.
Intralobar sequestration is located within a normal lobe and lacks its own visceral pleura. Both types are composed of normal lung tissue, including airway and alveolar elements.
![Page 154: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/154.jpg)
![Page 155: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/155.jpg)
Bronchopulmonary Sequestration
Histologically, pulmonary sequestrations demonstrate immature lung
development.
Extralobar sequestrations have anomalous blood supply from an
infradiaphragmatic source in about 20% of patients.
![Page 156: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/156.jpg)
Bronchopulmonary Sequestration
Intralobar sequestrations appear similar, on prenatal ultrasound, to a
CPAM. Can be associated with pleural effusion, polyhydraminos,
and nonimmune hydrops fetalis. Can be difficult to differentiate
from a CPAM or CDH by prenatal ultrasound. 60% occur on the
left side, most commonly left lower lobe.
90% extralobar sequestrations are located in the left hemithorax
within the posterior mediastinum. Sequestration in the upper lobe
occurs in only 10–15%, and bilateral sequestrations are rare.
![Page 157: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/157.jpg)
Bronchopulmonary Sequestration
Extralobar sequestrations generally present earlier than intralobar.
Infants with extralobar sequestrations typically present with respiratory distress and less commonly with recurrent pneumonia.
Intralobar sequestration usually present in late
childhood or adolescence with recurrent pulmonary infections.
![Page 158: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/158.jpg)
Bronchopulmonary Sequestration
Extralobar sequestrations often identified on antenatal U/S or in
infancy during surgery for other congenital anomalies such as
CPAM or CDH.
Most intralobar sequestrations present later in childhood due to
recurrent pulmonary infections.
The abnormally developed lung tissue is ineffective in gas exchange
and therefore is not of benefit to the patient. Spontaneous
involution of extralobar sequestrations has been described
![Page 159: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/159.jpg)
Bronchopulmonary Sequestration
Symptomatic patients, treatment is surgical excision, curative and is
associated with minimal morbidity.
Sx may be immediately after birth in severe RDS. Or electively in
older children who present with recurrent infections.
![Page 160: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/160.jpg)
![Page 161: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/161.jpg)
Intralobar pulmonary sequestration. CT scan showing calcified mass in left lower lobe
![Page 162: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/162.jpg)
Congenital pulmonary airway malformations (CPAM)
Previously congenital cystic adenomatoid malformations (CCAM)
Benign hamartomas or dysplastic tumors characterized by
overgrowth of terminal bronchioles in a glandular/adenomatoid
pattern.
Constitute 10–30% of congenital lung malformations.
Thought to result from marked overgrowth of the terminal bronchioles at the expense of alveoli development.
![Page 163: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/163.jpg)
Congenital pulmonary airway malformations (CPAM)
Generally unilobar with a slight predilection for the lower lobes,
with right and left sides affected equally.
Typically, have normal pulmonary arterial and venous blood
supply and communicate with the tracheobronchial tree.
Prenatal diagnosis by sonography is relatively common
![Page 164: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/164.jpg)
Congenital pulmonary airway malformations (CPAM)
Natural history determined more by overall size and
degree of compression of adjacent structures than by their
gross appearance.
Prenatal DDx includes congenital diaphragmatic hernia,
pulmonary sequestration, and bronchogenic cyst.
U/S findings associated with CPAM include
polyhydramnios, mediastinal shift, pleural effusions, and
fetal hydrops
![Page 165: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/165.jpg)
![Page 166: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/166.jpg)
![Page 167: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/167.jpg)
In antenatal and immediate postnatal period, main physiologic consequence of CPAM results from compression of the mediastinum and adjacent normal lung by the mass lesion.
Fetal hydrops identified in 40% of fetuses with CPAM and historically was an ominous finding, associated with a high risk of fetal or neonatal demise. Mortality approaches zero for a fetus with a CPAM but without hydrops
Spontaneous resolution in-utero of an antenatally diagnosed CPAM is reported in up to 15% of patients
Congenital pulmonary airway
malformations (CPAM)
![Page 168: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/168.jpg)
Congenital pulmonary airway
malformations (CPAM)
Most asymptomatic or undiagnosed CPAM will present
with infectious complications during childhood or
adolescence if not resected.
10% infectious complications by 3 yrs with unresected CPAM.
Pneumothorax and bronchiectasis are reported in association
with an untreated CPAM. Less commonly, a CPAM is
diagnosed in a child or during adulthood in association with a
pulmonary malignancy.
![Page 169: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/169.jpg)
Congenital Lobar Emphysema (CLO)
Characterized by expiratory air trapping within affected lobe.
Air trapping leads to overdistension of the affected lobe and
compression of the adjacent lung and mediastinal structures.
Lung parenchyma is typically normally developed, bronchial
collapse is commonly seen due to a focal deficiency or
absence of the cartilaginous components of the lobar
Bronchus.
![Page 170: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/170.jpg)
![Page 171: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/171.jpg)
Congenital Lobar Emphysema
Dx CLE is rarely made by antenatal US or MRI as
process of air trapping occurs postnatally.
Most commonly, the Dx CLE is made by plain chest X-ray
in newborn with RDS.
Most often affects the left upper lobe (40–50%), followed
by right middle lobe (30–40%), right upper lobe (20%).
![Page 172: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/172.jpg)
Congenital Lobar Emphysema
Associated with congenital heart disease in approximately
15% of patients and therefore screening echocardiography
is recommended.
50% affected infants will demonstrate signs of respiratory
distress in the first few days of life; the remainder develop
symptoms within the first few months or years of life.
![Page 173: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/173.jpg)
Bronchogenic Cysts
Bronchogenic cysts are typically thick walled, unilocular
cysts that originate from either the trachea or bronchus.
Believed to occur as a result of abnormal budding of the
tracheobronchial tree; hence can be found anywhere along the
conducting airways.
![Page 174: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/174.jpg)
Bronchogenic Cysts
Most often located within the lung parenchyma, mediastinum, or
in the neck; but ectopic bronchogenic cysts have been reported in
paravertebral, paraesophageal, pericardial, subcarinal, and
subcutaneous locations.
Many bronchogenic cysts are asymptomatic and discovered
incidentally by chest radiography.
![Page 175: CF Epidemiology: Australia](https://reader031.fdocuments.in/reader031/viewer/2022012408/616a3f2111a7b741a3506969/html5/thumbnails/175.jpg)
Bronchogenic Cysts
Most infants present with wheezing, tachypnea, dyspnea, and
cyanosis or less commonly, failure to thrive as a result of
compression of adjacent mediastinal structures. Older children
typically present with infectious complications.
Resection is typically indicated to alleviate symptoms, prevent
future infection, and to provide pathologic identification.